2-Aminoindanes

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.

Delapril (INN, also known as alindapril) is an ACE inhibitor used as an antihypertensive drug in some European and Asian countries but not in America. It is taken orally, available in 15 mg and 30 mg tablets.

Aprindine is a Class 1b antiarrhythmic agent of the 2-aminoindane family and has antiarrhythmic properties similar to lidocaine.

2-Aminoindane (2-AI) is a stimulant of the 2-aminoindane family which has been sold as a designer drug.

MDAI, also known as 5,6-methylenedioxy-2-aminoindane, is an entactogen of the 2-aminoindane family which is related to MDMA and produces similar subjective effects.

Indantadol (developmental code names CHF-3381, V-3381) is a drug of the 2-aminoindane family which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi. It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor, and as a low affinity, non-competitive NMDA receptor antagonist. A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in

'''N-Ethyl-5-trifluoromethyl-2-aminoindane (ETAI''') is a drug of the 2-aminoindane family with putative entactogenic effects. It functions as a serotonin releasing agent (SRA). ETAI is the 2-aminoindane analogue of fenfluramine and has approximately 50% of the serotonergic neurotoxicity in comparison.

PNU-99,194(A) (or U-99,194(A)) is a drug of the 2-aminoindane family which acts as a moderately selective D3 receptor antagonist with ~15-30-fold preference for D3 over the D2 subtype. Though it has substantially greater preference for D3 over D2, the latter receptor does still play some role in its effects, as evidenced by the fact that PNU-99,194 weakly stimulates both prolactin secretion and striatal dopamine synthesis, actions it does not share with the more selective (100-fold) D3 receptor antagonists S-14,297 and GR-103,691.

MEAI, also known as 5-methoxy-2-aminoindane (5-MeO-AI) and by its developmental code name CMND-100, is an entactogen-like psychoactive drug of the 2-aminoindane family. It is a cyclized phenethylamine and is the 2-aminoindane analogue of 3-methoxyamphetamine. The drug acts as a serotonin–norepinephrine releasing agent (SNRA) or as a modestly selective serotonin releasing agent (SSRA), with about 6-fold preference for induction of serotonin over norepinephrine release. MEAI has been encountered as a novel designer recreational drug. It is also under development for potential medical use in the

RDS-127, also known as '4,7-dimethoxy-N,N-dipropyl-2-aminoindane', is a drug of the 2-aminoindane family which is used in scientific research. It acts as a D2-like receptor agonist and also has some serotonin and adrenergic agonist effects, as well as some anticholinergic action, and produces both anorectic and pro-sexual effects in animal studies.

S-15535 is a phenylpiperazine drug which is a potent and highly selective 5-HT1A receptor ligand that acts as an agonist and antagonist (weak partial agonist) at the presynaptic and postsynaptic 5-HT1A receptors, respectively. It has anxiolytic and antiaggressive effects.